# Alpelisib and Capecitabine in Patients With PIK3CA Mutant mCRC Patients

> **NCT04753203** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Korean Cancer Study Group** · enrollment: 65 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer
- PIK3CA Gene Mutation

## Interventions

- **DRUG:** Alpelisib plus Capecitabine combination

## Key facts

- **NCT ID:** NCT04753203
- **Lead sponsor:** Korean Cancer Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-28
- **Primary completion:** 2024-02-28
- **Final completion:** 2025-02-28
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2023-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04753203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04753203, "Alpelisib and Capecitabine in Patients With PIK3CA Mutant mCRC Patients". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT04753203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*